Advances in adenoviral vectors: from genetic engineering to their biology

被引:136
作者
Yeh, P
Perricaudet, M
机构
[1] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy
[2] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy, 94805 Villejuif Cedex
关键词
adenovirus; viral capsid; DNA replication; gutless;
D O I
10.1096/fasebj.11.8.9240963
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ad2 and Ad5 belong to a group of human cytolytic viruses that target the respiratory airways for reproduction, whereas latent infections establish within other tissues. Signals therefore exist that control this dichotomic process in different cell types, perhaps including cis and/or trans elements of viral origin. Since 1993, Ad2- and Ad5-based adenoviruses lacking all or part of the El regulatory region have been undergoing evaluation in phase I trials that target cancer and cystic fibrosis. These viruses are extremely attenuated and actually do not reproduce in most human cells. However, they retain most of the virus genetic program and often promote a significant cytotoxicity after infection, emphasizing the need to further cripple the virus biology to extend the duration of transgene expression, if required. We will review the strategies currently followed to engineer a professional lytic virus for epithelial cells into an innocuous gene delivery vehicle. Potential effects on the transducing properties of the vector that may result from the inactivation of viral activities that normally allow/regulate extrachromosomal gene expression during wild-type infection are discussed.
引用
收藏
页码:615 / 623
页数:9
相关论文
共 50 条
  • [21] Stability of adenoviral vectors following catheter delivery
    Tsui, LV
    Zayek, N
    Frey, D
    Mello, C
    Banik, G
    Falotico, R
    McArthur, JG
    MOLECULAR THERAPY, 2001, 3 (01) : 122 - 125
  • [22] Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy
    Gao, Jian
    Zhang, Wenli
    Ehrhardt, Anja
    CANCERS, 2020, 12 (05)
  • [23] Delivery of adenoviral vectors to the prostate for gene therapy
    Yi Lu
    John Carraher
    Yu Zhang
    Jianling Armstrong
    Jody Lerner
    William P Rogers
    Mitchell S Steiner
    Cancer Gene Therapy, 1999, 6 : 64 - 72
  • [24] Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (Review)
    Bauerschmitz, GJ
    Barker, SD
    Hemminki, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 21 (06) : 1161 - 1174
  • [25] Gene transfer in kidney tubules and vasculature by adenoviral vectors
    Sukhatme, VP
    Cowley, BD
    Zhu, GM
    EXPERIMENTAL NEPHROLOGY, 1997, 5 (02): : 137 - 143
  • [26] Purification of adenoviral vectors using expanded bed chromatography
    Peixoto, C
    Ferreira, TB
    Carrondo, MJT
    Cruz, PE
    Alves, PM
    JOURNAL OF VIROLOGICAL METHODS, 2006, 132 (1-2) : 121 - 126
  • [27] Implications of the innate immune response to adenovirus and adenoviral vectors
    Gregory, Seth M.
    Nazir, Shoab A.
    Metcalf, Jordan P.
    FUTURE VIROLOGY, 2011, 6 (03) : 357 - 374
  • [28] Retargeting adenoviral vectors to improve gene transfer into tumors
    Hogg, R. T.
    Thorpe, P.
    Gerard, R. D.
    CANCER GENE THERAPY, 2011, 18 (04) : 275 - 287
  • [29] Adenoviral vectors and gene transfer to the blood vessel wall
    O'Brien, T
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) : 1414 - 1416
  • [30] Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
    Kerstetter, Lucas J.
    Buckley, Stephen
    Bliss, Carly M.
    Coughlan, Lynda
    FRONTIERS IN IMMUNOLOGY, 2021, 11